Neglected Tropical Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease (Dengue, Rabies, Trachoma, Buruli Ulcer, Yaws, Leprosy, Chagas Disease, Leishmaniasis, Soil-transmitted Helminthiases, and Others), By Product (Drugs and Vaccines), By Region & Competition, 2021-2031F
The Global Neglected Tropical Disease (NTD) Treatment Market is projected to expand from USD 7.99 billion in 2025 to USD 11.19 billion by 2031, achieving a compound annual growth rate of 5.77%. This market involves the creation and supply of pharmaceuticals and medical interventions aimed at combating communicable diseases common in tropical zones, such as soil-transmitted helminthiases and lymphatic filariasis. Growth in this sector is largely propelled by extensive medication donation programs organized by multinational pharmaceutical companies, along with significant financial support from philanthropic entities that subsidize research and access. Additionally, government-led mass drug administration initiatives serve as a crucial foundation, generating consistent demand for therapeutics and ensuring systematic delivery to at-risk populations.
However, market expansion is significantly hindered by the inadequacy of healthcare infrastructure in many endemic regions, which imposes severe logistical constraints on last-mile delivery to isolated communities. These supply chain deficiencies frequently interrupt treatment schedules and restrict the effective reach of global health programs. According to the International Federation of Pharmaceutical Manufacturers & Associations, approximately 900 million individuals worldwide received treatment for a neglected tropical disease in 2023. This statistic underscores the immense operational scale required to manage these conditions, despite the persistent logistical obstacles complicating delivery efforts.
Market Driver
The strategic execution of the WHO 2030 Roadmap and Eradication Targets serves as a primary market catalyst, shifting the global operational focus from disease control to the complete interruption of transmission. This policy framework encourages national governments to incorporate NTD programs into their core health systems, thereby increasing the procurement of essential diagnostic tools and therapeutic regimens required for certification. The roadmap?s emphasis on measurable milestones necessitates sustained demand for post-treatment surveillance technologies and the maintenance of medication stockpiles until elimination is verified. As reported by Uniting to Combat NTDs in their '2024: A year in review' released in December 2024, the global initiative achieved a critical milestone with 54 countries having eliminated at least one neglected tropical disease, confirming the market's trajectory toward eradication-driven demand.
Furthermore, increasing funding and grants from global health organizations, combined with robust public-private partnerships, provide the necessary financial liquidity for drug production and distribution in low-resource settings. Since commercial returns in this sector are limited, philanthropic capital and corporate donations are essential for sustaining the supply chain of critical medications like praziquantel and albendazole. These collaborative ventures not only finance research for new therapeutics but also subsidize the logistical costs of mass drug administration, bridging the gap between manufacturing and patient access. According to the 'Kigali Declaration on Neglected Tropical Diseases: 2022-2024 Progress Report' published by Uniting to Combat NTDs in October 2024, international partners have mobilized US$1.7 billion to support these goals. Additionally, Eisai Co., Ltd. reported in 2025 that it had provided a cumulative total of 2.51 billion diethylcarbamazine tablets to endemic regions, illustrating the vast scale of corporate contribution underpinning market stability.
Market Challenge
The deficiency of healthcare infrastructure in endemic regions constitutes a significant barrier to the growth of the Global Neglected Tropical Disease (NTD) Treatment Market. This challenge manifests as a severe logistical bottleneck where the supply chain for essential pharmaceuticals fractures before reaching the last mile. In many target areas, the absence of reliable transportation networks, climate-controlled storage facilities, and adequately equipped local clinics obstructs the consistent distribution of therapeutics. Even when international donation programs successfully mobilize vast quantities of medication, these infrastructure deficits frequently result in stockouts or product expiration at regional depots. Consequently, the market struggles to convert available inventory into administered treatments, stalling the operational momentum required to sustain global health initiatives.
The direct impact of these logistical failures is a persistent disconnect between the volume of medical interventions required and the actual number of patients served, which limits the addressable market size by rendering a significant portion of the population inaccessible. According to the World Health Organization, it was reported in 2024 that approximately 1.62 billion people globally required interventions for neglected tropical diseases. This statistic highlights that, despite the availability of treatments, a massive segment of the demand remains unmet primarily due to the inability to physically deliver care. This delivery shortfall impedes market expansion by reducing the efficacy of mass drug administration campaigns and discouraging the scaling of future investments.
Market Trends
The development of pediatric-specific formulations and child-friendly dosage forms is emerging as a crucial trend, addressing a historical treatment gap for younger demographics in endemic regions. Previously, mass drug administration campaigns were hindered by a lack of suitable options for preschool-aged children, often requiring the inaccurate crushing of adult tablets, which compromised safety and adherence. Pharmaceutical manufacturers are now prioritizing the engineering of dispersible, palatable tablets that ensure precise dosing and ease of administration for this vulnerable group. For instance, in March 2025, Merck announced in the press release 'First Preschool-Aged Child Receives Arpraziquantel for the Treatment of Schistosomiasis' that its newly developed dispersible tablet was successfully administered in an implementation study in Uganda, validating the market's progression toward inclusive therapeutic coverage for pediatric populations.
Simultaneously, the proliferation of Product Development Partnerships (PDPs) as the primary R&D model is structurally reshaping the innovation landscape, effectively circumventing the limited commercial incentives that restrict private sector investment. By consolidating resources from pharmaceutical companies, academic institutions, and philanthropic entities into a virtual research engine, these consortia are successfully driving the discovery of novel compounds and repurposing strategies. This collaborative framework is essential for maintaining a viable pipeline of therapeutics that individual corporations cannot sustain in isolation. Highlighting this trend, the Drugs for Neglected Diseases initiative (DNDi) noted in its '2024 Annual Report' released in July 2025 that it managed a diverse portfolio of 46 R&D projects, with 21 specifically focused on identifying or developing new chemical entities, underscoring the dominance of the PDP model in securing future treatments.
Key Market Players
In this report, the Global Neglected Tropical Disease (NTD) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Disease (NTD) Treatment Market.
Available Customizations:
Global Neglected Tropical Disease (NTD) Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
However, market expansion is significantly hindered by the inadequacy of healthcare infrastructure in many endemic regions, which imposes severe logistical constraints on last-mile delivery to isolated communities. These supply chain deficiencies frequently interrupt treatment schedules and restrict the effective reach of global health programs. According to the International Federation of Pharmaceutical Manufacturers & Associations, approximately 900 million individuals worldwide received treatment for a neglected tropical disease in 2023. This statistic underscores the immense operational scale required to manage these conditions, despite the persistent logistical obstacles complicating delivery efforts.
Market Driver
The strategic execution of the WHO 2030 Roadmap and Eradication Targets serves as a primary market catalyst, shifting the global operational focus from disease control to the complete interruption of transmission. This policy framework encourages national governments to incorporate NTD programs into their core health systems, thereby increasing the procurement of essential diagnostic tools and therapeutic regimens required for certification. The roadmap?s emphasis on measurable milestones necessitates sustained demand for post-treatment surveillance technologies and the maintenance of medication stockpiles until elimination is verified. As reported by Uniting to Combat NTDs in their '2024: A year in review' released in December 2024, the global initiative achieved a critical milestone with 54 countries having eliminated at least one neglected tropical disease, confirming the market's trajectory toward eradication-driven demand.
Furthermore, increasing funding and grants from global health organizations, combined with robust public-private partnerships, provide the necessary financial liquidity for drug production and distribution in low-resource settings. Since commercial returns in this sector are limited, philanthropic capital and corporate donations are essential for sustaining the supply chain of critical medications like praziquantel and albendazole. These collaborative ventures not only finance research for new therapeutics but also subsidize the logistical costs of mass drug administration, bridging the gap between manufacturing and patient access. According to the 'Kigali Declaration on Neglected Tropical Diseases: 2022-2024 Progress Report' published by Uniting to Combat NTDs in October 2024, international partners have mobilized US$1.7 billion to support these goals. Additionally, Eisai Co., Ltd. reported in 2025 that it had provided a cumulative total of 2.51 billion diethylcarbamazine tablets to endemic regions, illustrating the vast scale of corporate contribution underpinning market stability.
Market Challenge
The deficiency of healthcare infrastructure in endemic regions constitutes a significant barrier to the growth of the Global Neglected Tropical Disease (NTD) Treatment Market. This challenge manifests as a severe logistical bottleneck where the supply chain for essential pharmaceuticals fractures before reaching the last mile. In many target areas, the absence of reliable transportation networks, climate-controlled storage facilities, and adequately equipped local clinics obstructs the consistent distribution of therapeutics. Even when international donation programs successfully mobilize vast quantities of medication, these infrastructure deficits frequently result in stockouts or product expiration at regional depots. Consequently, the market struggles to convert available inventory into administered treatments, stalling the operational momentum required to sustain global health initiatives.
The direct impact of these logistical failures is a persistent disconnect between the volume of medical interventions required and the actual number of patients served, which limits the addressable market size by rendering a significant portion of the population inaccessible. According to the World Health Organization, it was reported in 2024 that approximately 1.62 billion people globally required interventions for neglected tropical diseases. This statistic highlights that, despite the availability of treatments, a massive segment of the demand remains unmet primarily due to the inability to physically deliver care. This delivery shortfall impedes market expansion by reducing the efficacy of mass drug administration campaigns and discouraging the scaling of future investments.
Market Trends
The development of pediatric-specific formulations and child-friendly dosage forms is emerging as a crucial trend, addressing a historical treatment gap for younger demographics in endemic regions. Previously, mass drug administration campaigns were hindered by a lack of suitable options for preschool-aged children, often requiring the inaccurate crushing of adult tablets, which compromised safety and adherence. Pharmaceutical manufacturers are now prioritizing the engineering of dispersible, palatable tablets that ensure precise dosing and ease of administration for this vulnerable group. For instance, in March 2025, Merck announced in the press release 'First Preschool-Aged Child Receives Arpraziquantel for the Treatment of Schistosomiasis' that its newly developed dispersible tablet was successfully administered in an implementation study in Uganda, validating the market's progression toward inclusive therapeutic coverage for pediatric populations.
Simultaneously, the proliferation of Product Development Partnerships (PDPs) as the primary R&D model is structurally reshaping the innovation landscape, effectively circumventing the limited commercial incentives that restrict private sector investment. By consolidating resources from pharmaceutical companies, academic institutions, and philanthropic entities into a virtual research engine, these consortia are successfully driving the discovery of novel compounds and repurposing strategies. This collaborative framework is essential for maintaining a viable pipeline of therapeutics that individual corporations cannot sustain in isolation. Highlighting this trend, the Drugs for Neglected Diseases initiative (DNDi) noted in its '2024 Annual Report' released in July 2025 that it managed a diverse portfolio of 46 R&D projects, with 21 specifically focused on identifying or developing new chemical entities, underscoring the dominance of the PDP model in securing future treatments.
Key Market Players
- F. Hoffmann-La Roche Ltd
- Sanofi S.A.
- Bayer AG
- GlaxoSmithKline plc
- Novartis AG
- Pfizer, Inc.
- Eisai Co., Ltd.
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Gilead Sciences, Inc.
In this report, the Global Neglected Tropical Disease (NTD) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Neglected Tropical Disease (NTD) Treatment Market, By Disease
- Dengue
- Rabies
- Trachoma
- Buruli Ulcer
- Yaws
- Leprosy
- Chagas Disease
- Leishmaniasis
- Soil-transmitted Helminthiases
- Others
- Neglected Tropical Disease (NTD) Treatment Market, By Product
- Drugs
- Vaccines
- Neglected Tropical Disease (NTD) Treatment Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Disease (NTD) Treatment Market.
Available Customizations:
Global Neglected Tropical Disease (NTD) Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease (Dengue, Rabies, Trachoma, Buruli Ulcer, Yaws, Leprosy, Chagas Disease, Leishmaniasis, Soil-transmitted Helminthiases, Others)
5.2.2. By Product (Drugs, Vaccines)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. NORTH AMERICA NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease
6.2.2. By Product
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Neglected Tropical Disease (NTD) Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease
6.3.1.2.2. By Product
6.3.2. Canada Neglected Tropical Disease (NTD) Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease
6.3.2.2.2. By Product
6.3.3. Mexico Neglected Tropical Disease (NTD) Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease
6.3.3.2.2. By Product
7. EUROPE NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease
7.2.2. By Product
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Neglected Tropical Disease (NTD) Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease
7.3.1.2.2. By Product
7.3.2. France Neglected Tropical Disease (NTD) Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease
7.3.2.2.2. By Product
7.3.3. United Kingdom Neglected Tropical Disease (NTD) Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease
7.3.3.2.2. By Product
7.3.4. Italy Neglected Tropical Disease (NTD) Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease
7.3.4.2.2. By Product
7.3.5. Spain Neglected Tropical Disease (NTD) Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease
7.3.5.2.2. By Product
8. ASIA PACIFIC NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease
8.2.2. By Product
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Neglected Tropical Disease (NTD) Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease
8.3.1.2.2. By Product
8.3.2. India Neglected Tropical Disease (NTD) Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease
8.3.2.2.2. By Product
8.3.3. Japan Neglected Tropical Disease (NTD) Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease
8.3.3.2.2. By Product
8.3.4. South Korea Neglected Tropical Disease (NTD) Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease
8.3.4.2.2. By Product
8.3.5. Australia Neglected Tropical Disease (NTD) Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease
8.3.5.2.2. By Product
9. MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease
9.2.2. By Product
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Neglected Tropical Disease (NTD) Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease
9.3.1.2.2. By Product
9.3.2. UAE Neglected Tropical Disease (NTD) Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease
9.3.2.2.2. By Product
9.3.3. South Africa Neglected Tropical Disease (NTD) Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease
9.3.3.2.2. By Product
10. SOUTH AMERICA NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease
10.2.2. By Product
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Neglected Tropical Disease (NTD) Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease
10.3.1.2.2. By Product
10.3.2. Colombia Neglected Tropical Disease (NTD) Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease
10.3.2.2.2. By Product
10.3.3. Argentina Neglected Tropical Disease (NTD) Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease
10.3.3.2.2. By Product
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. F. Hoffmann-La Roche Ltd
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Sanofi S.A.
15.3. Bayer AG
15.4. GlaxoSmithKline plc
15.5. Novartis AG
15.6. Pfizer, Inc.
15.7. Eisai Co., Ltd.
15.8. Astellas Pharma Inc.
15.9. Takeda Pharmaceutical Company Limited
15.10. Gilead Sciences, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease (Dengue, Rabies, Trachoma, Buruli Ulcer, Yaws, Leprosy, Chagas Disease, Leishmaniasis, Soil-transmitted Helminthiases, Others)
5.2.2. By Product (Drugs, Vaccines)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. NORTH AMERICA NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease
6.2.2. By Product
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Neglected Tropical Disease (NTD) Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease
6.3.1.2.2. By Product
6.3.2. Canada Neglected Tropical Disease (NTD) Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease
6.3.2.2.2. By Product
6.3.3. Mexico Neglected Tropical Disease (NTD) Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease
6.3.3.2.2. By Product
7. EUROPE NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease
7.2.2. By Product
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Neglected Tropical Disease (NTD) Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease
7.3.1.2.2. By Product
7.3.2. France Neglected Tropical Disease (NTD) Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease
7.3.2.2.2. By Product
7.3.3. United Kingdom Neglected Tropical Disease (NTD) Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease
7.3.3.2.2. By Product
7.3.4. Italy Neglected Tropical Disease (NTD) Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease
7.3.4.2.2. By Product
7.3.5. Spain Neglected Tropical Disease (NTD) Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease
7.3.5.2.2. By Product
8. ASIA PACIFIC NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease
8.2.2. By Product
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Neglected Tropical Disease (NTD) Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease
8.3.1.2.2. By Product
8.3.2. India Neglected Tropical Disease (NTD) Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease
8.3.2.2.2. By Product
8.3.3. Japan Neglected Tropical Disease (NTD) Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease
8.3.3.2.2. By Product
8.3.4. South Korea Neglected Tropical Disease (NTD) Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease
8.3.4.2.2. By Product
8.3.5. Australia Neglected Tropical Disease (NTD) Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease
8.3.5.2.2. By Product
9. MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease
9.2.2. By Product
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Neglected Tropical Disease (NTD) Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease
9.3.1.2.2. By Product
9.3.2. UAE Neglected Tropical Disease (NTD) Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease
9.3.2.2.2. By Product
9.3.3. South Africa Neglected Tropical Disease (NTD) Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease
9.3.3.2.2. By Product
10. SOUTH AMERICA NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease
10.2.2. By Product
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Neglected Tropical Disease (NTD) Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease
10.3.1.2.2. By Product
10.3.2. Colombia Neglected Tropical Disease (NTD) Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease
10.3.2.2.2. By Product
10.3.3. Argentina Neglected Tropical Disease (NTD) Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease
10.3.3.2.2. By Product
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL NEGLECTED TROPICAL DISEASE (NTD) TREATMENT MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. F. Hoffmann-La Roche Ltd
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Sanofi S.A.
15.3. Bayer AG
15.4. GlaxoSmithKline plc
15.5. Novartis AG
15.6. Pfizer, Inc.
15.7. Eisai Co., Ltd.
15.8. Astellas Pharma Inc.
15.9. Takeda Pharmaceutical Company Limited
15.10. Gilead Sciences, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
